Paper37348019
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Tolaney SM and 15 others. J Clin Oncol, 2023. Cited by 70 papers, by iCite.
Cite this record
ConductScience Library. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Papers, record 37348019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37348019
- Disease
- breast cancer1,032 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
- PubMed
- Publication types
- Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Humans | |
| Female | |
| Receptors, Estrogen | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Erb-b2 Receptor Tyrosine Kinases |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04059484 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | Results | Yes |
Source ClinicalTrials.gov
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28816986 | Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/28816986 | PubMed |
| 2 | 25380844 | Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. | Cancer Discov | 2015 | https://conductscience.org/library/papers/25380844 | PubMed |
| 3 | 27174596 | Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. | Nat Commun | 2016 | https://conductscience.org/library/papers/27174596 | PubMed |
| 4 | 30206110 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. | Cancer Discov | 2018 | https://conductscience.org/library/papers/30206110 | PubMed |
| 5 | 29289555 | Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. | Pharmacol Ther | 2018 | https://conductscience.org/library/papers/29289555 | PubMed |
| 6 | 30555626 | DNA damage repair defects as a new class of endocrine treatment resistance driver. | Oncotarget | 2018 | https://conductscience.org/library/papers/30555626 | PubMed |
| 7 | 32979513 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). | Ann Oncol | 2020 | https://conductscience.org/library/papers/32979513 | PubMed |
| 8 | 20632084 | Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). | Breast Cancer Res Treat | 2010 | https://conductscience.org/library/papers/20632084 | PubMed |
| 9 | 26947331 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/26947331 | PubMed |
| 10 | 35584336 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35584336 | PubMed |
| 11 | 29860922 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29860922 | PubMed |
| 12 | 28580882 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28580882 | PubMed |
| 13 | 34392831 | ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. | Breast Cancer Res | 2021 | https://conductscience.org/library/papers/34392831 | PubMed |
| 14 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 15 | 27908454 | Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/27908454 | PubMed |
| 16 | 30205045 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30205045 | PubMed |
| 17 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 18 | 27269946 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269946 | PubMed |
| 19 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 20 | 38729567 | A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. | Ann Oncol | 2024 | https://conductscience.org/library/papers/38729567 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42948694 | Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2- advanced breast cancer. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42948694 | PubMed |
| 42927396 | Retrospective Analysis of Real-World Elacestrant Use in Two Large Austrian Cancer Centers. | Breast Care (Basel) | 2026 | https://conductscience.org/library/papers/42927396 | PubMed |
| 42816507 | ERα Micromap (µMap) proximity labeling reveals fulvestrant mechanisms. | Nat Commun | 2026 | https://conductscience.org/library/papers/42816507 | PubMed |
| 42761341 | Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42761341 | PubMed |
| 42755923 | Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence. | Front Oncol | 2026 | https://conductscience.org/library/papers/42755923 | PubMed |
| 42657161 | Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/42657161 | PubMed |
| 42510955 | Targeting Estrogen Receptor for Breast Cancer. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42510955 | PubMed |
| 42449621 | Oral Estrogen Receptor Degraders Compared to Standard Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449621 | PubMed |
| 42445743 | Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42445743 | PubMed |
| 42401911 | Sex differences in non-reproductive cancers: mechanistic roles of sex-hormone signaling. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42401911 | PubMed |
| 42311745 | Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals. | Cureus | 2026 | https://conductscience.org/library/papers/42311745 | PubMed |
| 42045295 | Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42045295 | PubMed |
| 41999452 | Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/41999452 | PubMed |
| 41917040 | Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/41917040 | PubMed |
| 41704390 | Allosteric Induction of Estrogen Receptor Ligand Binding Domain Tetramerization by a Distinct Complete Estrogen Receptor Antagonist. | ACS Med Chem Lett | 2026 | https://conductscience.org/library/papers/41704390 | PubMed |
| 41654790 | Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41654790 | PubMed |
| 41572375 | Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer. | Breast Cancer Res | 2026 | https://conductscience.org/library/papers/41572375 | PubMed |
| 41420679 | CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41420679 | PubMed |
| 41241883 | Advances and challenges of estrogen receptor-targeted agents in breast cancer. | Arch Pharm Res | 2025 | https://conductscience.org/library/papers/41241883 | PubMed |
| 41097702 | Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097702 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP19A1 | 1588 | PubTator's text mining | https://conductscience.org/library/genes/1588 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| GNRH1 | 2796 | PubTator's text mining | https://conductscience.org/library/genes/2796 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
Drugs6
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| EXEMESTANE | CHEMBL1200374 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1200374 | ChEMBL |
| FULVESTRANT | CHEMBL1358 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1358 | ChEMBL |
| ANASTROZOLE | CHEMBL1399 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1399 | ChEMBL |
| LETROZOLE | CHEMBL1444 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1444 | ChEMBL |
| AMCENESTRANT | CHEMBL4475463 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4475463 | ChEMBL |
| TAMOXIFEN | CHEMBL83 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL83 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37348019
GET https://conductscience.org/api/papers/v1/37348019/references?page=2